Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.

Hirak S BasuNathaniel WilganowskiSamantha RobertsonJames M ReubenEvan N CohenAmado ZuritaSumankalai RamachandranLian-Chun XiaoMark TitusGeorge Wilding

Published in: The Prostate (2021)

The enhanced growth inhibitory effects of mitochondrial metabolic inhibitors IACS and CB-839 in ENZA pretreated PCa cells provides a rationale for designing a drug combination trial. Patients can be selected for such trials by monitoring the mitochondrial ETS activities in their CTCs to maximize success.

Keyphrases

oxidative stress
end stage renal disease
induced apoptosis
clinical trial
chronic kidney disease
signaling pathway
transcription factor
randomized controlled trial
study protocol
cell death
endoplasmic reticulum stress
patient reported outcomes
electronic health record